Terumo (Terumo) Forward PE Ratio

: 0.00 (As of Today)

View and export this data going back to 2008. Start your Free Trial

Terumo's Forward PE Ratio for today is 0.00.

Terumo's PE Ratio without NRI for today is 36.51.

Terumo's PE Ratio for today is 36.51.

Terumo Forward PE Ratio Historical Data

The historical data trend for Terumo's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo Annual Data

Trend

2018-12

2019-12

2020-12

2021-12

2022-12

2023-12

2024-01

Forward PE Ratio

22.99

30.12

33.78

31.55

23.42

25.13

27.62

Terumo Quarterly Data
	2018-03	2018-06	2018-09	2018-12	2019-03	2019-06	2019-09	2019-12	2020-03	2020-06	2020-09	2020-12	2021-03	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12
Forward PE Ratio	25.19	28.01	30.58	22.99	50.00	26.88	28.74	30.12	27.47	31.45	43.29	33.78	34.60	39.22	38.02	31.55	24.15	28.41	27.55	23.42	22.57	29.07	25.06	25.13

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Terumo's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Terumo Forward PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Terumo's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Terumo's Forward PE Ratio falls into.

Terumo Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Terumo (OTCPK:TRUMY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Terumo Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Terumo's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Terumo (Terumo) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (OTCPK:TRUMY) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

TRUMF:USA 4543:Japan TUO:Germany

Address

2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072

Website

https://www.terumo.com

Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.